CAR-T and cellular therapy at ASH 2020

CLL Society Ed Forum: ASH 2020 Comes to You - William Wierda, MD, PhDПодробнее

The Future of CAR T Cell TherapiesПодробнее

Can novel immunotherapies cure multiple myeloma?Подробнее

CAR T-cell therapy for relapsed ALL with CNS involvementПодробнее

Emerging lymphoma therapies: bispecific antibodies and CAR T-cellsПодробнее

Lymphoma Research Highlights from ASH 2020Подробнее

ASH 2020 Meeting Highlights in Multiple MyelomaПодробнее

Optimizing CAR T cell therapies in lymphoma Improving response, fighting cytokine release syndromeПодробнее

Latest Myeloma Research Updates from the ASH 2020 MeetingПодробнее

CAR T-cell therapy horizon scanПодробнее

Lummicar-2: CT053 for R/R multiple myelomaПодробнее

ASH 2020: Overview of the current advances in treating aggressive NHLПодробнее

Combining CAR T-cell therapy with targeted drugs—can we improve efficacy in patients with R/R CLL?Подробнее

Improving CAR T-cell therapy for myelomaПодробнее

CAR T-cell therapy for high-risk multiple myelomaПодробнее

FHVH-BCMA-T CAR T-cell therapy shows efficacy in R/R myelomaПодробнее

Major study data to look out for from ASH 2020Подробнее

2020 American Society of Hematology Webinar | LRF WebinarsПодробнее

Emerging immunotherapies for myelomaПодробнее

ASH 2020 Updates: CAR T Cell Therapies in Multiple MyelomaПодробнее